Immuron Limited CEO Presentation at Coffee Microcaps Conference

Immuron Limited, an Australian biopharmaceutical company, announced that its CEO, Steven Lydeamore, will present at the Coffee Microcaps VIP Conference on September 16, 2025. The presentation will cover Immuron's focus on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases. The company's flagship product, Travelan®, is an orally administered passive immunotherapy that reduces the risk of travelers' diarrhea. Immuron is also developing IMM-529, an adjunctive therapy for recurrent Clostridioides difficile infection (CDI), and has an exclusive distribution agreement for ProIBS® in Australia and New Zealand. The presentation will highlight Immuron's proprietary technology, clinical development programs, and upcoming milestones.